RxDoctor Payments Data

Thomas Holt, MD

Family Medicine · Tallassee, ALNPI 1306848494

Payments from drug & device makers

$604in general payments, 2019–2025

Across 38 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$119
  • Acadia Pharmaceuticals Inc$78
  • Sanofi-aventis U.S. LLC$58
  • Avanir Pharmaceuticals, Inc.$51
  • AstraZeneca$43
  • Pfizer$32
  • plus $223 from 10 others

What the payments were for

  • Food & beverage$604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$604 in reported general payments places this provider in the 45th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$213,094
Medicare patients
432
Services billed
2,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,686$538,069
NuplazidPimavanserin Tartrate121$301,088
JanuviaSitagliptin Phosphate421$144,221
IngrezzaValbenazine Tosylate29$111,588
Invega SustennaPaliperidone Palmitate34$102,700
TrulicityDulaglutide77$77,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$59,919
LinzessLinaclotide96$56,631
XareltoRivaroxaban147$50,178
JardianceEmpagliflozin138$48,194
GemtesaVibegron172$45,055
SantylCollagenase Clostridium Hist.52$42,938
MyrbetriqMirabegron159$42,639
OzempicSemaglutide36$39,511
EntrestoSacubitril/Valsartan106$35,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$32$561,0321,759 claims
Acadia Pharmaceuticals IncNuplazid$78$301,088121 claims
Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta$31$169,256211 claims
MerckJanuvia, Janumet$28$158,575471 claims
Neurocrine Biosciences, Inc.Ingrezza$19$111,58829 claims
Lilly USA, LLCTrulicity$29$77,12877 claims
AbbVieLinzess, Viberzi$11$73,156119 claims
Astellas Pharma US IncMyrbetriq$14$42,639159 claims
Novo NordiskOzempic$17$39,51136 claims
NovartisEntresto$119$35,650106 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$29$24,86220 claims
Avanir Pharmaceuticals, Inc.Nuedexta$51$19,15323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Tallassee

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →